Ervebo
Ervebo is a vaccine developed for the prevention of Ebola virus disease (EVD) caused by the Zaire ebolavirus. It is the first vaccine to be approved for the prevention of EVD and has been a significant advancement in the fight against Ebola outbreaks.
Development[edit | edit source]
Ervebo was developed by Merck & Co., a major pharmaceutical company. The vaccine is based on a live attenuated recombinant vesicular stomatitis virus (rVSV) that has been genetically engineered to express a glycoprotein from the Zaire ebolavirus. This glycoprotein is responsible for inducing an immune response in the vaccinated individual.
Clinical Trials[edit | edit source]
The development of Ervebo involved several phases of clinical trials. Initial trials were conducted to assess the safety and immunogenicity of the vaccine. Subsequent trials, including large-scale efficacy trials, were conducted in regions affected by Ebola outbreaks, particularly in West Africa during the 2014-2016 Ebola outbreak.
Approval and Use[edit | edit source]
Ervebo received approval from the European Medicines Agency (EMA) in November 2019 and from the U.S. Food and Drug Administration (FDA) in December 2019. The vaccine has been used in various Ebola outbreak responses, including the 2018-2020 outbreak in the Democratic Republic of the Congo.
Mechanism of Action[edit | edit source]
Ervebo works by introducing a harmless virus that carries a protein from the Ebola virus. This protein triggers the body's immune system to produce antibodies against the Ebola virus, providing immunity to the vaccinated individual.
Administration[edit | edit source]
The vaccine is administered as a single-dose intramuscular injection. It is recommended for individuals who are at high risk of exposure to the Ebola virus, including healthcare workers and people living in or traveling to areas with active Ebola transmission.
Impact[edit | edit source]
The introduction of Ervebo has had a significant impact on the control of Ebola outbreaks. It has provided a critical tool for protecting healthcare workers and vulnerable populations, thereby reducing the spread of the virus and the mortality associated with Ebola outbreaks.
See Also[edit | edit source]
- Ebola virus disease
- Zaire ebolavirus
- Merck & Co.
- European Medicines Agency
- U.S. Food and Drug Administration
- Democratic Republic of the Congo
- West Africa
References[edit | edit source]
External Links[edit | edit source]
 | This article about vaccines or vaccination is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
